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Abstract
The term refractory migraine has been used to describe persistent headache that is difficult to treat or fails to respond
to standard and/or aggressive treatments. This subgroup of migraine patients are generally highly disabled and
experience impaired quality of life, despite optimal treatments. Several definitions and criteria for refractory migraine
have been published, but as yet, an accepted or established definition is not available. This article reviews the
published criteria and proposes a new set of criteria. The epidemiology, pathophysiology and management
options are also reviewed.
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Introduction
Migraine is a chronic paroxysmal neurological disorder
characterised by attacks of moderate or severe headache
and reversible neurological and systemic symptoms. The
most characteristic symptoms associated with migraine
include photophobia, phonophobia, and gastrointestinal
symptoms such as nausea and vomiting [1]. The man-
agement of migraine includes identifying and excluding
secondary headache types, addressing comorbid factors,
and optimizing both pharmacological management and
behavioural treatments. Although much progress has
been made in recent years in the management of mi-
graine, there remains a group of patients who continue
to experience disabling headache despite optimal treat-
ment. These patients remain “refractory” or “intractable”
to standard treatment. However, universally accepted defi-
nitions of “refractory” or “intractable” are not available.
Historical perspective
The term “refractory migraine” was first used by Reisman
in 1952 when he reported the use of suppositories of
ergot-alkaloids to treat migraine [2]. However, little atten-
tion was subsequently paid to this term until just over a
decade ago. Over the last decade there have been several
attempts to define refractory migraine albeit that there is
still a lack of consensus on this issue.
Goadsby et al proposed a definition of intractable
migraine and cluster headaches in 2006 [3]. It required
the failure of four preventive drugs applicable to the type
of headache being treated. Acute treatments and degree
of disability were not included in these criteria. In 2008,
the Refractory Headache Special Interest Section (RHSIS)
of the American Headache Society (AHS) definition of
refractory migraine were published [4]. These criteria re-
quired only failure of two classes of preventive treatments.
In addition, patients needed to fail 3 classes of acute treat-
ments. Medication overuse and degree of disability were
included as modifiers. Silberstein et al proposed a defin-
ition for pharmacologically intractable headache in 2010
[5]. They build upon the AHS criteria, proposing a graded
classification scheme for intractability to acute and
preventive treatments as well as rating of headache-related
disability. The European Headache Federation (EHF)
provided a consensus statement on the definition of
chronic migraine (CM) in 2014 [6]. These criteria are
restricted to CM and require the failure of three classes of
preventive treatments. They require adequate treatment
of psychiatric or other comorbidities by a multidisciplinary
team, if available, but acute treatments and degree of
disability were not included in these criteria.
An overview of these proposals reveals that there is a
lack of consensus on the definition of refractory migraine
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as well as the factors included in their operational criteria
(see Table 1).
Importance of defining refractory migraine
There are numerous reasons to better define and
characterize refractory migraine [5–7]. A widely ac-
cepted definition of refractory migraine will allow better
characterization of the disorder and enable identification
of the optimum therapeutic strategy. The epidemiology
of refractory migraine in population samples is unknown
and the unmet medical need of the patients is largely
undefined. In the Refractory Headache Survey conducted
by the AHS, the estimated prevalence of refractory
migraine in responders’ practice ranged from “less than
5%” to “greater than 31%” (median 5–10%) [7]. It is
unknown whether there are differences in the clinical
phenotype, genetic makeup, or serum and neuroimaging
biomarkers of refractory patients compared to those
who are responsive to treatments.
Improved recognition of refractory migraine will help
patients obtain the appropriate level of care. The headache
characteristics, drug usage, disability status and comorbid
features are often used to stage illness and triaging of pa-
tients to the proper level of care [8]. This may include a
multidisciplinary approach, utilizing behavioural medicine
and psychological support. The most effective treatment
for refractory migraine, whether there should be various
levels of triage, and who should be assigned to what level,
remains unclear. Defining and studying this group will en-
able characterisation of the current patterns of treatments
and possibly help identify the best treatment modalities.
It would be useful to identify the risk factors for devel-
oping refractory migraine. Migraine is a progressive
disorder in some patients and modifiable risk factors for
progression include obesity, caffeine, medication, overuse,
and sleep problems [9]. Migraineurs with major depres-
sion reported physical and sexual abuse in higher frequen-
cies compared with those without depression [10].
Whether these factors are also important in refractory
migraine is unclear. There are currently no biological
markers that predict migraine progression. Identification
of biomarkers for refractory migraine has the potential to
stimulate research into disease-modifying agents [11].
Patients with refractory migraine are often excluded
from clinical trials, particularly of novel pharmacological
approaches. Defining this group of patients could serve
as the criteria for inclusion in clinical trials. Conversely,
in some device trials, refractoriness is defined as having
failed only two different preventative medications [12,
13]. This seems a rather low threshold definition of re-
fractory migraine for an invasive device trial. Interest-
ingly, Goadsby et al criticised the patent foramen ovale
trialists for performing a device trial in patients who
were only required to fail two preventive treatments, yet
some of these authors have themselves subsequently
performed invasive device trials using similar inclusion
criteria [3, 14]. Better definition of refractory migraine
will enable the appropriate patients to be recruited to
interventional clinical trials.
Nomenclature
The terms refractory headache and intractable headache
have been used interchangeably to describe headache that
is difficult to treat or fails to respond to standard headache
treatments. The term “intractable” has the following
meanings: unmanageable, uncontrollable, impossible to
cope with; difficult, troublesome, demanding, refractory
and burdensome. The term “refractory” has the following
meanings: unmanageable, recalcitrant, intractable. These
terms therefore have definitions that appear to overlap.
While it has been acknowledged that establishing a con-
sistent nomenclature is important and therefore using a
single term is preferable, there is nonetheless disagree-
ment about which term to use. Some authors have advo-
cated the use of the term “intractable” [3, 5] while others
have opted for “refractory” [4, 6].
While both these terms are clearly synonymous, both
the AHS and EHF consensus statements have used the
term “refractory” and therefore this should be the pre-
ferred term hereon in [4, 6].
Requirements for determining refractoriness
A clear understanding of the pathophysiological mecha-
nisms underlying refractory headache are lacking; there-
fore, establishing a definition or classification scheme
based on mechanism (s) is not currently possible. The
diagnosis of refractory headache has therefore been
based on headache characteristics, the response to
pharmacological and non-pharmacological treatments,
and headache-related disability (See Table 1).
Headache diagnosis
The specific headache type must be ascertained using
the International Classification of Headache Disorders
(ICHD) criteria before assessing refractoriness to treat-
ment. The ICHD classification criteria are widely accepted
and it would be reasonable to expect clinicians and clinical
trialists to use the latest iteration of these criteria.
The EHF criteria for refractory migraine [6] are limited
to CM while the AHS criteria [4] include both episodic
migraine (EM) and CM. While both EM and CM patients
can be refractory to treatments, there is a case to be made
for keeping these two groups separate. Though EM and
CM are part of the spectrum of migraine disorders, they
are nonetheless distinct clinical entities. CM is a distinct
disorder with clinical, epidemiological, sociodemographic,
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Table 1 Overview of the published proposal for refractory or intractable migraine
Goadsby et al. (2006) Schulman et al. (2008) Silberstein et al. (2010) Martelletti et al. (2014)
Headache Diagnosis
Diagnostic
criteria
Not stated ICHD diagnostic criteria ICHD diagnostic criteria ICHD diagnostic criteria
Episodic or
Chronic
Migraine
Not stated Both included Inclusion of both episodic and
chronic migraine not explicitly stated
but implicitly included as criteria
pertain to all primary headaches
Limited to chronic migraine
Medication
overuse
Not stated With or without medication overuse
(as defined by ICHD criteria) included
as modifier
Not stated No medication overuse
Acute Treatments
Inclusion in
operational
criteria
Criteria limited to
preventive treatments
only
Included in refractoriness criteria Included in refractoriness criteria Criteria limited to preventive
treatments only
Number of
acute
treatments
failed
Not applicable Both of the following 2 classes Grading system proposed:
Mild: failed class1
Moderate: failed classes 1–3
Severe: failed classes 1–4
Not applicable
Acute
classes
Not applicable 1. Both a triptan and DHE intranasal
or injectable formulation
2. Either nonsteroidal anti-
inflammatory drugs or combination
analgesics
1. Non-specific acute treatments (eg,
NSAIDs, combination analgesics)
2. Triptans or ergot derivatives
3. Oral dopamine antagonists or
parenteral NSAID
4. Oral or parenteral opioids or
corticosteroids or parenteral
dopamine antagonists
Not applicable
Preventive treatments
Number of
classes
failed
4 classes (including 3
from 1 to 4)
2 of 4 classes: Grading system proposed:
Mild: failed 1 of cases 1–10
Moderate: failed 2 drugs where 1
must be from classes 1–6
Severe: failed 3 drugs where 2 must
be from classes 1–6
Very severe: Above plus failed
aggressive infusion or inpatient
treatment and/or failure to respond
to detoxification treatment in subjects
with acute headache pain medication
overuse
3 drugs from following
classes
Preventive
classes
1. Beta-blockers
2. Anticonvulsants
3. Calcium channel
blockers
4. Tricyclic
antidepressants
5. Other treatments
with at least one
positive randomised
controlled trial
6. Non-steroidal anti-
inflammatory drugs
7. Metabolic
enhancers
1. Beta-blockers
2. Anticonvulsants
3. Tricyclics
4. Calcium channel blockers
1. Beta-blockers (shown to be
effective)
2. Tricyclic antidepressants
3. Verapamil or flunarizine
4. Sodium valproate (or divalproex
sodium)
5. Topiramate
6. Combination therapy that includes
at least 1 drug of type 1–5; the
second drug can be from any type
(1-5 or 6-9). The drugs must be of
different types (eg, a combination of
2 anticonvulsants is not acceptable)
7. Gabapentin
8. Other treatments with at least 1
positive placebo-controlled trial
9. Non-steroidal anti-inflammatory
drugs
10. Metabolic enhancers (Vitamin B2
or CoQ10)
1.Beta blockers (propranolol
up to 240mg/d; metoprolol
up to200mg; atenolol up
to100mg; bisoprolol up
to10mg)
2.Anticonvulsants (valproate
acid up to 1,5 g/d;
topiramate up to 200mg/d)
3.Tricyclics (amitriptyline up
to 150mg/d)
4.Others (flunarizine up to 10
mg/d; candesartan 16mg/d)
5.OnabotulinumtoxinA (155–
195 U according to the
PREEMPT protocol)
Headache-
Related
Disability
Disabled by standard
scales e.g. MIDAS, HIT-
6 or scale suitable in
Included as a modifier, with patients
classified as having significant
disability if MIDAS > 11
Disability measured using MIDAS or
HIT-6
Not included
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and comorbidity profiles as well as therapeutic response
patterns different from that of EM [15]. Separate criteria
need to be developed for refractory EM and refractory
CM rather than lumping them together.
Regarding medication overuse headache (MOH), the
EHF criteria for refractory migraine require that this entity
should be ruled out or be adequately treated before a pa-
tient can be classified as refractory [6]. On the other hand,
the AHS criteria allow MOH patients to be included but
apply a modifier to distinguish patients with and without
MOH [4]. MOH can be both the cause and the conse-
quence of the refractoriness hence the reason that the EHF
committee elected to exclude MOH. However, a distinc-
tion needs to be made between “medication overuse” and
“medication overuse headache”. Some patients with CM
and medication overuse undergo drug withdrawal, remain
abstinent from abortive treatments for prolonged periods
of time, remain refractory to preventive treatments and
subsequently revert to overusing abortive treatments. Pa-
tients who may have MOH should be excluded but pa-
tients with medication overuse after exclusion of MOH
should be included, albeit that the patients with and with-
out medication overuse need to be studied separately.
Pharmacological treatment failure
Abortive or preventive treatments?
The AHS criteria and Silberstein et al require failure to
respond to both abortive and preventive treatments to
classify a patient as refractory as one treatment alone
would not be considered optimal [4, 5]. However, there
are operational difficulties with these criteria, for ex-
ample, a CM patient with highly disabling daily head-
aches who responds well to abortive treatments but has
failed to respond to numerous preventive treatments
would not qualify to be categorised as a refractory pa-
tient. In view of this, the EHF criteria are only based on
non-responsiveness to preventive treatments. The EHF
committee take the view that the key for success in CM
is prevention (rather than abortive treatment) and re-
fractoriness is a consequence of prophylactic failure [6].
Refractoriness to abortive and preventive treatments
are distinct issues. The mechanism of action of acute
and preventive treatments, at least for some agents, are
different. Refractoriness to acute treatments may not
correlate with refractoriness to preventive treatments. In
view of this, separate criteria need to be developed for
each without conflating the two into one set of criteria.
The main challenge in clinical practice is refractory CM
and the primary focus in this group should be on pre-
ventive treatments.
Which and how many preventive treatments?
In preventive headache treatment, refractoriness is de-
fined as failure to respond or contraindications/ intoler-
ance to proven preventive therapies. Table 1 shows the
preventive treatments that are outlined by the various
criteria for refractory migraine. Some of the treatments
Table 1 Overview of the published proposal for refractory or intractable migraine (Continued)
Goadsby et al. (2006) Schulman et al. (2008) Silberstein et al. (2010) Martelletti et al. (2014)
country of assessment
Lifestyle
factors
Not addressed Criteria state that headaches should
cause “significant interference with
function or quality of life despite
modification of triggers, and lifestyle
factors” but no operational criteria
provided
Considered by authors but excluded Not included
Comorbidities Not addressed Not addressed Considered by authors but excluded Adequate treatment of
psychiatric or other
comorbidities by
multidisciplinary team, if
available.
Definition of
failed trial
No therapeutic or
unsatisfactory effecta
Intolerable side effects
Contraindications to
use
Not defined Not defined No therapeutic effecta
Contraindications to use
Definition of
adequate
trials
Appropriate dosea
Appropriate durationa
Period of time during which an
appropriate dose of medicine is
administered, typically at least 2
months at optimal or maximum
tolerated dose, unless terminated
early due to adverse effects
Not defined Prophylactic migraine
medications in adequate
dosages used for at least 3
months each.
DHE Dihydroergotamine, HIT-6 Headache Impact Test, ICHD International Classification of Headache Disorders, MIDAS Migraine Disability Assessment Test
aNot further defined
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are common to all the criteria (beta-blockers, anticonvul-
sants, tricyclic antidepressants) while others have listed
treatments that have a poor evidence base especially in
CM. The only preventive treatments that have a good
evidence base for efficacy in CM include topiramate [16],
Onabotulinumtoxin A [17] and calcitonin gene related
peptide (CGRP) pathway monoclonal antibodies [18]. This
poses the challenging issue of whether it is appropriate for
refractory CM criteria to require trials of treatments that
have a poor evidence base.
While the counsel of perfection would be to only use
treatments that have a good evidence base in CM, this
will prove to be difficult in practise as Onabotulinum-
toxin A and CGRP pathway monoclonal antibodies are
difficult to access in some/most healthcare systems. A
pragmatic compromise would be to use treatments in
CM that have an evidence base for efficacy (2 class I or
2 class II based on American Academy of Neurology
Scheme for classification of evidence) in EM [19]. The
recent AHS consensus statement on integrating new
migraine treatments into clinical practice reviewed the
evidence base for treatment of migraine and recom-
mended the use of anticonvulsants, betablockers, tricyc-
lic antidepressants, serotonin-noradrenaline reuptake
inhibitors, Onabotulinumtoxin A and CGRP pathway
monoclonal antibodies to treat CM [20].
The number of preventive medicine classes necessary
to meet the criteria for refractory migraine is another
vexing issue. The number of classes of treatments re-
quired by the various proposals ranges between two and
four. Failure of two preventive treatments, recom-
mended by the AHS criteria, seems to be a rather low
threshold definition for refractory migraine. This partly
pertains to the fact that the term refractory headache is
used in various clinical settings (e.g., primary care vs
tertiary specialty care), for diverse interventions (e.g., re-
ferral to a specialist; enrolment into prophylactic drug
study), and different intensities of the intervention (e.g.,
hospitalization; enrolment into a device or intracranial
surgery trial). The AHS committee seems to have set a
rather low threshold to accommodate the use of this
term in diverse settings for very differing interventions
[4]. Silberstein et al have attempted to provide a graded
classification scheme but the operational criteria are
cumbersome for clinical practice [5]. It seems inappro-
priate to outlie a set of criteria that on the one hand
prompt primary care physicians to refer patients to sec-
ondary care and on the other hand are used for defining
patients who might be suitable for invasive headache
treatments; these groups are diverse and require differ-
ent criteria rather than trying to merge into one group.
At the other end of the spectrum, requiring failure to all
treatments would be unrealistic, particularly since, in the
absence of evidence, national practice varies so much.
The threshold for the number of clinical trials should
ideally be set by ascertaining the number of trials beyond
which there are diminishing returns. However, this issue
has not been studied thus far in CM. Until this issue is
systematically studied, any threshold for the number of
preventive treatments required for defining refractori-
ness will continue to be arbitrary. The authors view is
that the threshold of even three or four preventive treat-
ments is too low and consideration needs to be given to
failure to respond to five treatments especially when
invasive treatments, such as occipital nerve stimulation,
are being considered.
Definition of an adequate trial
An adequate trial is defined as a period of time during
which an appropriate dose of medicine is administered at
an optimal or maximum-tolerated dose, unless terminated
early due to adverse effects. Specific criteria for the dur-
ation of treatment required for determining failure is not
well-defined and varies throughout the literature. The
AHS and EHF criteria require two- and 3-month trials, re-
spectively, at an optimum dose. This duration does not in-
clude the time taken for the gradual upward titration of
the dose. The issue of the adequate duration of trial
cannot be settled as no controlled trials that provide for
length of treatment have been performed. While longer
trials would be preferred by clinicians, patients are often
keen to move onto a trial of another drug if there has been
no beneficial effect after 2 months at an optimum dose.
Definition of failed trial of preventive treatment
What constitutes a failed trial of a preventive treatment?
The current criteria for a failed trial are vague or simply
not defined. An operational definition is required. The
endpoint used in clinical trials (> 50% reduction in head-
ache days or migraine days) seems too robust for clinical
practice. Indeed, in chronic pain, a 30% reduction in
pain (frequency and/or severity) often translates into a
meaningful improvement in quality of life albeit that
even with this level of improvement the patient may still
be highly disabled by the headache disorder [21]. How-
ever, accepting a threshold of a 30% improvement for a
succesful trial runs the risk of being criticised for setting
the bar too low.
Patients can fail a trial of a preventive treatment, even
when used for a short duration or at a suboptimal dose, if
they have intolerable side effects. Some patients have med-
ical contraindications to the use of specific preventive
treatments thereby potentially lowering the threshold for
meeting the criteria for refractoriness; these contraindi-
cated agents should only counted amongst the “failed
trials” if after all other potential preventive treatments that
can be used have been tried.
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Non-pharmacological treatment failure
A number of meta-analytic studies have shown that bio-
feedback, relaxation, and cognitive–behaviour therapy are
efficacious for migraine [22]. However, behavioural treat-
ments are less accessible than pharmacological treatment
and more variable in their application. In view of this the
AHS committe elected to define refractory migraine as
failure of response to pharmacological rather than non-
pharmacological treatments [4]. The EHF committee, on
the other hand, require adequate treatment of psychiatric
or other comorbities by a multidisciplinary team, if avail-
able, but do not provide any operational criteria [6].
While trigger, behavioural and nonpharmacological
management of patients is a staple of good clinical
practice, incorporating all of these variables into a clas-
sification scheme, intended for clinical practice inter-
ventions or clinical trial eligibility would be complex,
difficult to use, overly cumbersome, and bordering on
prohibitive [5].
Headache-related disability
The role of disability in defining and classifying refrac-
tory headaches has not been clearly established. The
term refractory headache by itself does not infer or
reflect disability. If a headache is frequent and untreat-
able, but has no disabling impact on the patient, it may
be appropriate to do nothing, but it still is considered as
refractory [5]. Both the AHS and EHF criteria have not
included headache-related disability in the criterion for
refractoriness, though the AHS criteria include disability
measured using MIDAS (Migraine Disability Assessment
Test) as a modifier.
While it would clearly be imperative to only recruit
patients with severe headache-related disability (as mea-
sured by well validated headache-related disability scores
e.g. headache impact test-6 [HIT-6] and Migraine Phys-
ical Function Impact Diary [MPFID]) into invasive trials,
these measures should not be used to define refractory
headache [23, 24].
Refractory chronic migraine criteria: a personal
perspective
Any criteria proposed for defining refractory CM needs
to be operational otherwise they are open to varying in-
terpretations. The authors recommendations for defining
it are outlined in Table 2. Patients need to satisfy the
ICHD-III classification criteria for CM and MOH need
to be excluded. However, patients who are currently
overusing abortive medications but have previously
failed to benefit from withdrawal of medications (i.e.
have medication overuse but not medication overuse
headache) can be included. Patients need to fail five clas-
ses of preventive treatments including two of the three
agents/classes that have a good evidence base for efficacy
in CM (topiramate, Onabotulinumtoxin A, CGRP path-
way monoclonal antibodies), provided they are available
in the local healthcare system. There are several mi-
graine preventive treatments in development [25]; the
proposed criteria will allow inclusion of these treatments
as and when there is a good evidence base for their use.
An adequate trial needs to be performed for at least 2
months at the optimum dose (excluding the time taken
to titrate the dose) unless terminated early due to side
effects. Failure to respond to a drug is defined by less
than 50% reduction in frequency and/or severity of
Table 2 Proposed criteria for refractory chronic migraine
Criteria Definition
A. Primary Diagnosis 1. ICHD-III chronic migraine
2. Medication overuse headache excludeda
B. Refractory Failure to respond to 5 classes of preventive treatments (including 2 from 1 to 3b):
1. Topiramate
2. Minimum of two quarterly injections of Onabotulinumtoxin A
3. CGRP pathway monoclonal antibody
4. Betablockers (Propranolol, Metoprolol, Timolol)
5. Tricyclic antidepressant (Amitriptyline)
6. SNRI (Venlafaxine)
7. Sodium valproate/Divalproex sodium
8. Other pharmacological preventive treatments with established efficacy in migrainec
C. Adequate Trial At least 2 month trial at an optimum or maximum tolerated dose (excluding the time
taken for the titration o the dose), unless terminated early due to side effectsd
D. Failed Trial 1. Failure to respond to drug (< 50% reduction in frequency and/or severity of monthly
migraine days)
2. Intolerable side effects
3. Contraindication to use
CGRP calcitonin gene related peptide, ICHD International Classification of Headache Disorders, SNRI Serotonin-noradrenaline reuptake inhibitor
aPatients who overuse abortive treatments can be included provided medication overuse headache has been excluded
bApplicable if available in the local healthcare system
c2 class I or 2 class II based on American Academy of Neurology Scheme for classification of evidence [19]
dOptimum dose defined as that used in the controlled trials demonstrating efficacy or as outlined by local treatment guidelines
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monthly migraine days, intolerable side effects or contra-
indication to use.
Epidemiology
While refractory migraine patients are commonly seen
in headache specialty clinics, the epidemiology of this
subtype of migraine is poorly studied. The only pub-
lished study reported on 370 consecutive patients at-
tending a tertiary referral headache clinic [26]. Nineteen
patients (5.1%) fulfilled the AHS criteria for refractory
migraine. The mean age was 43 years and 58% were fe-
male. Seventy-nine percent had refractory CM and 21%
had refractory EM. Thirty-six percent had MOH.
Pathophysiology
Migraine is a multiphasic complex disorder that involves
multiple pathways and several neurotransmitter systems.
The interested reader is referred to some excellent re-
views on the pathophysiology of migraine [27–29]. The
pathophysiological basis of refractoriness in migraine is
unknown though may include impaired modulation and
hyperexcitability resulting in upregulation of pronocicep-
tive systems, structural changes and genetic heterogeneity.
Upregulation of pronociceptive systems may rendering
some migraine sufferers’ refractory to standard pharma-
cotherapy, especially in the setting of acute medication
overuse. Peripheral and central sensitization occur dur-
ing migraine attacks [30]. Moreover, when examined
during a pain free state, some patients with CM exhibit
cutaneous allodynia and lowered thermal and mechan-
ical pain thresholds indicating the potential for activity
independent sensitization to occur in some migraine suf-
ferers. The mechanisms involved in central sensitization
may include the release of glutamate, substance P, and
CGRP from primary afferent neurons, glutamate activa-
tion of N-methyl-D-aspartate receptors (NMDA), and
activation of glial cells [31]. The upregulation o the pro-
nociceptive mechanism may be at such a high level in
refractory migraine patients that the currently available
treatments are unable to wind down these mechanisms.
Multiple neurotransmitter pathways are involved in the
pathophysiology of migraine and the prominence of any
one particular pathway may differ substantially between
patients. There is evidence of an important role for dopa-
mine, serotonin, glutamate, orexin, nitric oxide, CGRP,
and others in the pathogenesis of migraine. It is therefore
unlikely that a drug which targets any single receptor type
or subtype will provide robust efficacy for all migraine suf-
ferers or prevail as the treatment of choice. Patients with
refractory migraine may have prominence of pathways
which the existing drugs do not modulate.
Evidence is increasing for functional and structural brain
changes that appear to occur with increasing migraine fre-
quency. Key structural differences in cortical thickness in
the somatosensory cortex and insula were found in indi-
viduals with high migraine attack frequency, indicating
the potential for repeated sensory activation during attacks
to lead to adaptive changes in regions of the brain that
process sensory information and modulate the affective
response to pain [32]. Additionally, as migraine frequency
increases, stronger activation is seen in regions that facili-
tate pain and weaker activation is seen in regions that
inhibit pain [33]. In a structural imaging study, brain cor-
tical thickness, cortical surface area, and regional volumes
were highly accurate in distinguishing individuals with
CM from those with EM and nonaffected controls [34].
These functional and structural changes may play a role in
rendering some patients refractory to pharmacotherapeu-
tic agents.
A meta-analysis of genome wide association studies in-
volved 59,674 affected individuals and 316,078 controls
from 22 studies has recently been reported [35]. Overall,
38 distinct genomic loci were found to be significantly
associated with migraine risk. The genes identified are in-
volved in ion channels, glutamatergic neurotransmission,
and neuronal and synapse development; these genes could
influence the enhanced cortical excitability that is charac-
teristic of migraine. Genes expressed in vascular and
smooth muscle tissues were also identified, indicating that
vascular homoeostasis could influence the expression of
the disease and might be integral to the pathogenesis of
migraine, at least in some subgroups with migraine. Gen-
etic heterogeneity is likely to be a major determinant of
the heterogeneity of response to pharmacotherapeutic
agents.
Management of Refractory Migraine
There are several reasons why standard headache treat-
ments fail [36–38]. These reasons include incomplete or
inaccurate diagnosis, important exacerbating factors and
comorbidities have been missed, non-pharmacological
treatment has been inadequate, pharmacotherapy has
been inadequate, neuromodulation has not been consid-
ered and unrealistic expectations by patients. These fac-
tors should be systematically considered in the clinical
evaluation of patients with refractory migraine.
Review the diagnosis
The diagnosis can be incomplete or inaccurate. This issue
takes three major forms: a secondary headache disorder
goes undiagnosed, a primary headache disorder is mis-
diagnosed, or two or more headache disorders are present
and at least one goes unrecognized. When managing
patients with treatments-refractory headaches, it is im-
portant to re-evaluate the headache phenotype periodic-
ally to ensure that the diagnosis is accurate and, when
necessary, perform any pertinent investigations to exclude
secondary headaches.
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Identify important exacerbating factors and comorbidities
Important exacerbating factors include medication over-
use, dietary or lifestyle triggers, hormonal triggers, psycho-
social factors, or the use of other medications that trigger
headaches (eg, phosphodiesterase inhibitors, nitrates) and
may lead to refractoriness. In the search for exacerbating
factors, ask about factors the patient may have identified
and then probe for common and uncommon exacerbating
factors, especially those that are subject to modification or
intervention.
In headache subspecialty practices, medication overuse
and withdrawal is a common cause of refractoriness
[39]. It is therefore important to specifically establish the
patient’s pattern of medication use, including both pre-
scription and over-the counter medication. Patients are
often embarrassed about medication misuse and fear
that the physician will make harsh judgments. It is there-
fore important to ask about medication use in an open,
non-judgmental manner.
Numerous population-based epidemiological and clinic-
based research studies have established the higher preva-
lence of major depression, bipolar disorder, anxiety, panic
disorders, and obsessive- compulsive disorder in patients
with migraine compared with the general population and
to non-migraine headache sufferers [40, 41]. There is
emerging evidence to suggest that psychiatric comorbidity
contributes both to the progression of headache and to the
treatment refractoriness of a considerable number of pa-
tients [42]. Depressed patients are less likely to adhere to
medication regimens, are more likely to become discour-
aged with less than robust or timely results, while anxious
patients are fearful of side effects which precludes titration
to effective dosages or fearful of headache which drives
medication overuse [43]. Identifying these psychiatric
comorbidities and consulting the expertise necessary to
effectively manage these psychiatric disorders are therefore
essential to effectively managing patients with refractory
migraine.
Sleep and headache are intimately related. Over- or
under sleeping may cause headache, and yet, sleep may
relieve headache. Common sleep disorders associated with
headache include obstructive sleep apnoea (OSA), peri-
odic leg movement disorder, insomnia, hypersomnia, and
circadian rhythm disorders [44]. Headache upon awaken-
ing is common with OSA. Insomnia, the most common
sleep disorder associated with headache, may reflect anx-
iety. Routinely screen refractory migraine patients for
sleep disorders. There are a numerous validated scales in
sleep medicine, such as the Pittsburgh Sleep Quality Index
(PSQI), that may be used for screening [45].
Educate the patient about lifestyle factors
The aim is to help the patient identify precipitating or ex-
acerbating factors and to encourage their modification as
well as implement a lifestyle that will make patient less
prone to migraine. Rather than making a long list of
things to avoid, patients should be encouraged to have
regular habits. Inform patients that regular sleep, exercise,
meals, hydration, work habits and relaxation are likely to
be rewarded by a reduction in headache frequency [46].
Patients should be encouraged to limit the intake of caf-
feine and alcohol. There is no well-controlled evidence
that specific diets ameliorate migraine.
Consider biobehavioural therapies
Biobehavioural therapy, including cognitive behavioural
therapy (CBT) and biofeedback, and relaxation therapies
have been shown to be effective in the acute and pre-
ventive treatment of migraine [47, 48]. Biobehavioural
therapies may be used alone or in conjunction with
Table 3 Treatment options in the management of refractory migraine
Oral/Nasal Injectable Neurostimulation
Acute • Oral and Intranasal Triptans
• High dose NSAIDS
• Paracetamol
• Antiemetics
• Subcutaneous sumatriptan • Transcranial magnetic stimulation
• External trigeminal nerve stimulation
(Cefaly)
• Vagal nerve stimulation
Preventive • Beta-blockers: Propranolol, Metoprolol,
Timolol, Atenolol, Nadolol
• Anticonvulsants: Topiramate, Valproate
• Tricyclics: Amitriptyline
• SNRI: Venlafaxine
• Angiotensin pathway blockers: Lisinopril,
Candesartan
• Calcium channel blockers: Flunarizine
• Nutraceuticals: Riboflavin, Coenzyme Q10,
Magnesium, Feverfew
• Onabotulinumtoxin A
• CGRP-pathway monoclonal
antibodies
• External trigeminal nerve stimulation
(Cefaly)
• Transcranial magnetic stimulation
• Occipital nerve stimulation
• High cervical spinal cord stimulation
Transitional • Corticosteroids • Greater occipital nerve block
• Multiple cranial nerve blocks
• Intravenous dihydroergotamine
• Intravenous lidocaine
NSAIDS Non-steroidal anti-inflammatory drugs
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pharmacologic and interventional treatments. Evidence
suggests that combining biobehavioural interventions
with pharmacotherapy provides greater benefits than
either modality alone [49].
Optimise pharmacotherapy
The choice of abortive and preventive treatment agents
should be based on evidence based guidelines [20, 50].
Systematically trial and optimize the abortive and prevent-
ive treatments. These treatments options are outlined in
Table 3.
The primary focus of treatments in refractory migraine
is on preventive strategies. The success of preventive
therapy rests as much on the strategy employed when
initiating and titrating the medication and establishing
realistic patient expectations as it does on which drug is
actually selected [51]. Patients often report that they
have failed to respond to multiple preventive treatments;
however, it is commonplace to learn that the medications
which were not effective or could not be tolerated were
never used appropriately. Hence, resorting to some of the
basic principles outlined below can often enhance out-
comes [37].
Start the chosen drug at a low dose and increase slowly
by weekly dose increments until therapeutic effects de-
velop. Set an initial target dose and advise the patient to
stop prior to reaching the target dose if significant benefit
emerges or side effects are noted. However, all too often,
the target dose is considered the ceiling dose. If intolerable
side effects are not present, the dose can continue to be
increased until efficacy is acceptable and/or optimal. Give
each treatment an adequate trial of at least 2 months at
the maximal tolerated dose or minimal effective dose.
A drug may be selected (e.g. antidepressant in a
migraineur with depression) or avoided (beta-blocker in
a migraineur with asthma) based on the presence of a
comorbid or coexistent illness. However, care should be
taken not to undertreat a comorbid disorder by trying to
treat two different conditions with one drug.
The common side effects and their frequency in con-
trolled studies should be discussed with patients prior to
initiating the trial. Patients often select preventive medica-
tions based on side effect profiles they most want to avoid.
Therefore, patient preference must be considered as they
are more likely to be compliant with a medication they
helped select. Most side effects are self-limiting and
attenuate over time. Patients should be educated to expect
and encouraged to tolerate the early side effects that may
develop when a new medication is started. In this way, a
substantial reduction in the frequency and severity of
migraine attacks may be realized before reflexively with-
drawing or discontinuing a therapy prematurely.
Set the expectations for success. Success is defined as: a
50% reduction in attack frequency, a significant decrease in
attack duration/severity or an improved response to acute
medication. Unless educated, some patients understandably
interpret the term “prevention” literally and anything less
than complete relief of attacks is equated with “failure” of
the drug.
While there is a paucity of controlled evidence to sup-
port the use of two or more preventive medications for
the treatment of migraine, it is a useful and rational tech-
nique in patients who are poorly responsive or considered
refractory. This is especially true if a “partial” response is
seen with one medication. Combining medications with a
presumably different mechanism of action may also yield
therapeutic results, minimize the dosage of each medica-
tion, and therefore, minimize the side effect profile of
each.
Given that preventative medications can take several
weeks to exert their full effect, patients often wish to
quickly control attack frequency, especially if they are
having frequent very severe headache. These patients
may benefit from a transitional or bridging treatment.
These interventions are not suitable for long-term use
and so often require concurrent use with traditional pre-
ventative agents. A short course of steroids and nerve
blocks can be considered, albeit that the evidence base
for their use is relatively sparse [52–56].
When outpatient treatment fails and patients have
continuing and severe pain and disability, inpatient level
treatment interventions may be required. Detoxification
(if necessary) can be carried out and aggressive parenteral
treatments initiated to break the headache cycle initiated.
Treatments such as intravenous dihydroergotamine and
intravenous lidocaine can be used in this setting [57].
Attendant medical and psychological issues can be ad-
dressed, and pharmacologic and nonpharmacologic main-
tenance treatment can be optimised.
Consider non-invasive and invasive neuromodulation
Several noninvasive devices have been developed for the
treatment of patients with migraine. These treatments
modulate pain mechanisms involved in headache by
stimulating the nervous system centrally or peripherally
with an electric current or a magnetic field [58]. The de-
vices available include single-pulse transcranial magnetic
stimulation for the acute and preventive treatment of
migraine, electrical trigeminal nerve stimulation for the
acute and preventive treatment of migraine, and nonin-
vasive vagus nerve stimulation for the acute treatment of
migraine.
In highly refractory and severely disabled patients who
fail to respond to most pharmacotherapeutic agents and
non-invasive devices (when available), invasive neurosti-
mulation can be considered. The options include occipi-
tal nerve stimulation and high cervical spinal cord
stimulation [12, 59, 60].
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Utilise a multidisciplinary approach
The lack of a comprehensive multimodal and multidiscip-
linary approach underlies the refractoriness of a substantial
proportion of migraine sufferers who do not respond to
currently available therapies [37]. These patients can re-
quire input from psychiatry for diagnosing and managing
comorbid psychiatric disorders as well as pain psychologists
for cognitive behavioural therapy, biofeedback and relax-
ation therapy. Input from pain medicine or neurosurgeons
may be required for interventional procedures such as
nerve blocks and invasive neuromodulation.
Conclusion
Refractory migraine poses a challenge for both patients
and clinicians. The patients experience high levels of dis-
ability and impaired quality of life. Clinicians struggle to
effectively manage these patients. Succesfully managing
these patients requires enlisting multiple modalities of
therapies, often within the context of a multidisciplinary
team. Establishing operational criteria that are widely ac-
cepted is clearly needed to eliminate the current disarray
in the literature. The premise of the criteria proposed
herein is that the currently published proposals have a
relatively low threshold for defining refractory migraine
and are not operational. Standardisation of these criteria
as well as validation and further refinements through
field testing will be essential for further progress in this
area. The pathophysiology of refractory migraine is
poorly understood; a better understanding of the patho-
physiology of this entity is urgent needed so that better
treatments can be developed for this patient group.
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